The case for prescribing methotrexate (MTX) as a steroid-sparing agent in established Polymyalgia Rheumatica (PMR) has been bolstered with new Australian evidence showing it improves inflammatory markers and reduces prednisolone dose in some patients who were unable to wean corticosteroids. A retrospective observational study looked at 70 patients attending two outpatient clinics in South Australia. ...
Australian study fills evidence gap for MTX as steroid-sparing agent in PMR
By Sunalie Silva
25 Feb 2020